Morningstar18d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis ...
pharmaphorum9d
4th ALS Drug Development Summit
The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...
Pharmabiz17d
QurAlis announces positive data from phase 1 trial of QRL-101 evaluating biomarkers of ALS and epilepsy in healthy volunteers
QurAlis Corporation (QurAlis), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Yahoo Finance18d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ...